WuXi Biologics’ MFG8 Drug Substance Facility Secures FDA PLI Approval, Advancing Commercial Supply of a Potential Blockbuster Autoimmune Therapy

SHIJIAZHUANG, China, July 9, 2026 /PRNewswire/ — WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that its MFG8 drug substance manufacturing facility located in Hebei has successfully passed the Pre-License… Source: prnewswire Country: United States

Rosen Law Firm Encourages Gildan Activewear Inc. Investors to Inquire About Securities Class Action Investigation – GIL

NEW YORK, July 9, 2026 /PRNewswire/ — Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Gildan Activewear Inc. (NYSE: GIL) resulting from allegations that Gildan Activewear may have issued materially… Source: prnewswire Country: United States